Literature DB >> 3466890

Immunochemical aspects of monoclonal antibodies important for radiopharmaceutical development.

S J DeNardo, J S Peng, G L DeNardo, S L Mills, A L Epstein.   

Abstract

Successful development of radiopharmaceuticals from monoclonal antibodies will require the control of several immunochemical aspects of the antibody molecules. A proposed set of methods is presented here for evaluating these immunochemical parameters. This approach consists of monitoring each monoclonal antibody harvest by selective affinity chromatography to determine the presence of detectable alterations in molecular homogeneity. The products are then evaluated by radioimmunoassay technique standardized for total immunoglobulin immunoreactivity. These assays are utilized to detect variation in the immunoreactivity secondary to changes in the hybridoma cell lines, and to measure any detectable denaturation secondary to purification, fragment production and radiolabeling. HPLC molecular sieving chromatography is presented as a practical and informative monitor of molecular stability of these radiopharmaceuticals in vitro and in vivo.

Mesh:

Substances:

Year:  1986        PMID: 3466890     DOI: 10.1016/0883-2897(86)90002-4

Source DB:  PubMed          Journal:  Int J Rad Appl Instrum B        ISSN: 0883-2897


  4 in total

1.  The remarkable stability of chimeric, sialic acid-derived alpha/delta-peptides in human blood plasma.

Authors:  Jonel P Saludes; Arutselvan Natarajan; Sally J DeNardo; Jacquelyn Gervay-Hague
Journal:  Chem Biol Drug Des       Date:  2010-05       Impact factor: 2.817

2.  Macrocyclic chelates of radiometals for diagnosis and therapy.

Authors:  C F Meares; M K Moi; H Diril; D L Kukis; M J McCall; S V Deshpande; S J DeNardo; D Snook; A A Epenetos
Journal:  Br J Cancer Suppl       Date:  1990-07

3.  Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 anti-c-erbB-2 single-chain Fv: effects of dose escalation and repeated i.v. administration.

Authors:  G P Adams; J E McCartney; E J Wolf; J Eisenberg; M S Tai; J S Huston; W F Stafford; M A Bookman; L L Houston; L M Weiner
Journal:  Cancer Immunol Immunother       Date:  1995-05       Impact factor: 6.968

4.  Tumor targeting in a murine tumor xenograft model with the (sFv')2 divalent form of anti-c-erbB-2 single-chain Fv.

Authors:  J S Huston; G P Adams; J E McCartney; M S Tai; R M Hudziak; H Oppermann; W F Stafford; S Liu; I Fand; G Apell
Journal:  Cell Biophys       Date:  1994
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.